Cargando…

Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors

BACKGROUND: The presence of cachexia in cancer patients negatively affects the quality of life and survival. However, the impact of cachexia on immunotherapy, such as PD‐1/L1 inhibitors, is not fully understood. Therefore, we examined whether cancer cachexia affects the prognosis of patients with no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuo, Norikazu, Azuma, Koichi, Murotani, Kenta, Murata, Daiki, Matama, Goushi, Kawahara, Akihiko, Kojima, Takashi, Tokito, Takaaki, Hoshino, Tomoaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212657/ https://www.ncbi.nlm.nih.gov/pubmed/37037511 http://dx.doi.org/10.1111/1759-7714.14881

Ejemplares similares

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Murata, Daiki, et al.
Publicado: (2023)

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor‐induced interstitial lung disease in patients with non‐small cell lung cancer
por: Murata, Daiki, et al.
Publicado: (2022)

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC
por: Ishii, Hidenobu, et al.
Publicado: (2020)

Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy
por: Ishii, Hidenobu, et al.
Publicado: (2017)

A case of cytokine release syndrome accompanied with COVID‐19 infection during treatment with immune checkpoint inhibitors for non‐small cell lung cancer
por: Murata, Daiki, et al.
Publicado: (2022)

Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model
por: Azuma, Koichi, et al.
Publicado: (2022)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy
por: Ishii, Hidenobu, et al.
Publicado: (2017)

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
por: Ishii, Hidenobu, et al.
Publicado: (2020)

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples
por: Ishii, Hidenobu, et al.
Publicado: (2015)

Clinical significance of high monocyte counts for the continuous treatment with nintedanib
por: Tsuneyoshi, Shingo, et al.
Publicado: (2023)

Correction to: clinical significance of high monocyte counts for the continuous treatment with nintedanib
por: Tsuneyoshi, Shingo, et al.
Publicado: (2023)

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs
por: Masuda, Ken, et al.
Publicado: (2018)

Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor
por: Zaizen, Yoshiaki, et al.
Publicado: (2018)

A Rare Case of Diffuse Bilateral Minute Pulmonary Meningothelial-like Nodules Increasing over the Short Term and Resembling Metastatic Lung Cancer
por: Murata, Daiki, et al.
Publicado: (2022)

Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy
por: Matsuo, Norikazu, et al.
Publicado: (2019)

Positive Autoantibody Is Associated with Malignancies in Patients with Idiopathic Interstitial Pneumonias
por: Koga, Takuma, et al.
Publicado: (2022)

Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
por: Azuma, Koichi, et al.
Publicado: (2014)

Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade
por: Saisho, Chika, et al.
Publicado: (2016)

Proton Beam Therapy as a Curative Treatment for a Young Case of Unresectable Tracheal Adenoid Cystic Carcinoma
por: Kinoshita, Takashi, et al.
Publicado: (2023)

Periostin Is a Biomarker of Rheumatoid Arthritis-Associated Interstitial Lung Disease
por: Matama, Goushi, et al.
Publicado: (2023)

Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures
por: Wei, Feifei, et al.
Publicado: (2023)

The Characteristic of Transbronchial Lung Cryobiopsy in the Pathological Diagnosis of Hypersensitivity Pneumonitis
por: Ohno, Shuuhei, et al.
Publicado: (2023)

Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
por: Yamashita, Fumie, et al.
Publicado: (2013)

Interleukin-8 and clinical symptoms can be prognostic indicators for advanced cancer patients with cachexia
por: Murai, Miyo, et al.
Publicado: (2020)

Granulomatous Lymphocytic Interstitial Lung Disease in Multiple Myeloma
por: Sasaki, Jun, et al.
Publicado: (2022)

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
por: Azuma, Koichi, et al.
Publicado: (2014)

Pazopanib for treating rhabdomyosarcoma in adult patients with poor performance status: A case report
por: Nishii, Yuuya, et al.
Publicado: (2022)

Ghrelin for cachexia
por: Akamizu, Takashi, et al.
Publicado: (2010)

Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy
por: Hayashi, Naomi, et al.
Publicado: (2021)

Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
por: ISHII, HIDENOBU, et al.
Publicado: (2014)

Pathophysiology of cachexia and characteristics of dysphagia in chronic diseases
por: Matsuo, Haruyo, et al.
Publicado: (2022)

Anti-Ku antibody-positive desquamative interstitial pneumonia
por: Otoshi, Ryota, et al.
Publicado: (2018)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Successful Treatment of a Patient with Drug-Refractory Rheumatoid Arthritis-Associated Interstitial Lung Disease with Upadacitinib: A Case Report
por: Nishii, Yuuya, et al.
Publicado: (2023)

AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
por: Murakami, Yuichi, et al.
Publicado: (2022)

Clinical impact of lipid injectable emulsion in internal medicine inpatients exclusively receiving parenteral nutrition: a propensity score matching analysis from a Japanese medical claims database
por: Takagi, Kosei, et al.
Publicado: (2022)

Dose-Dependent Effects of Amino Acids on Clinical Outcomes in Adult Medical Inpatients Receiving Only Parenteral Nutrition: A Retrospective Cohort Study Using a Japanese Medical Claims Database
por: Takagi, Kosei, et al.
Publicado: (2022)

Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass
por: Sakuma, Kunihiro, et al.
Publicado: (2012)

Registry study of immune-related adverse events using electronic patient-reported outcome in patients with cancer receiving immune checkpoint inhibitors: protocol for a multicentre cohort study
por: Hirata, Taiki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7uqabqnseivqcdnc680hsqe4t8